These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37270367)

  • 21. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records.
    Kislaya I; Peralta-Santos A; Borges V; Vieira L; Sousa C; Ferreira B; Pelerito A; Gomes JP; Leite PP; Nunes B; ; Machado A; Rodrigues AP; Peixoto VR; Casaca P; Fernandes E; Rodrigues E; Ferreira R; Isidro J; Pinto M; Duarte S; Santos D; Meneses L; Almeida JP; Matias A; Freire S; Grilo T
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13121. PubMed ID: 36935845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia.
    Wong MTJ; Dhaliwal SS; Balakrishnan V; Nordin F; Norazmi MN; Tye GJ
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    Price AM; Olson SM; Newhams MM; Halasa NB; Boom JA; Sahni LC; Pannaraj PS; Irby K; Bline KE; Maddux AB; Nofziger RA; Cameron MA; Walker TC; Schwartz SP; Mack EH; Smallcomb L; Schuster JE; Hobbs CV; Kamidani S; Tarquinio KM; Bradford TT; Levy ER; Chiotos K; Bhumbra SS; Cvijanovich NZ; Heidemann SM; Cullimore ML; Gertz SJ; Coates BM; Staat MA; Zinter MS; Kong M; Chatani BM; Hume JR; Typpo KV; Maamari M; Flori HR; Tenforde MW; Zambrano LD; Campbell AP; Patel MM; Randolph AG;
    N Engl J Med; 2022 May; 386(20):1899-1909. PubMed ID: 35353976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study.
    Tang L; Zhang Y; Wang F; Wu D; Qian ZH; Zhang R; Wang AB; Huang C; Wang H; Ye Y; Lu M; Wang C; Ma YT; Pan J; Li YF; Lv XY; An Z; Rodewald L; Wang XY; Shao YM; Wu ZY; Yin Z
    BMJ Open; 2022 Nov; 12(11):e063919. PubMed ID: 36368753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert.
    Temsah MH; Aljamaan F; Alenezi S; Alhasan K; Alrabiaah A; Assiri R; Bassrawi R; Alhaboob A; Alshahrani F; Alarabi M; Alaraj A; Alharbi NS; Halwani R; Jamal A; Al-Eyadhy A; AbdulMajeed N; Alfarra L; Almashdali W; Fayed A; Alzamil F; Barry M; Memish ZA; Al-Tawfiq JA; Alsubaie S
    Front Public Health; 2022; 10():878159. PubMed ID: 35400032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
    Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
    Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiological and clinical features of SARS-CoV-2 infection in children during the outbreak of Omicron variant in Shanghai, March 7-31, 2022.
    Wang X; Chang H; Tian H; Zhu Y; Li J; Wei Z; Wang Y; Xia A; Ge Y; Liu G; Cai J; Zhu Q; Zhai X; Zeng M
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1059-1065. PubMed ID: 36043446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).
    Kiss Z; Wittmann I; Polivka L; Surján G; Surján O; Barcza Z; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Pálosi M; Szlávik J; Schaff Z; Szekanecz Z; Müller C; Kásler M; Vokó Z
    Front Immunol; 2022; 13():905585. PubMed ID: 35812442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.
    Tartof SY; Frankland TB; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Aug; 5(8):e2225162. PubMed ID: 35921109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: A world-wide review.
    Wang C; Liu B; Zhang S; Huang N; Zhao T; Lu QB; Cui F
    J Med Virol; 2023 Jan; 95(1):e28118. PubMed ID: 36056540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study.
    Thi Hong Nguyen N; Ou TY; Huy LD; Shih CL; Chang YM; Phan TP; Huang CC
    Front Public Health; 2023; 11():1145138. PubMed ID: 37333556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
    Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.